AIHTA - Publications - Search - Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC)

Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Oncology Fact Sheet Nr. 82.

[thumbnail of Oncology Fact Sheet Nr.82.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
133kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 250 Oesophagus
Language:English
Series Name:Oncology Fact Sheet Nr. 82
Deposited on:28 Mar 2022 12:39
Last Modified:16 May 2022 09:34

Repository Staff Only: item control page